Informação sobre produto
- 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea
- Orgovyx
- Rvt 601
- TAK-385,Relugolix
- Tak-385
- Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxy-
Relugolix is a hormone antagonist that blocks the effects of androgens such as testosterone. It is used to treat prostate cancer, endometriosis, and other conditions. Relugolix has been shown to be an effective treatment for prostate cancer when used in combination with other therapies such as platinum-based chemotherapy or radiation therapy. Relugolix has been shown to block not only the effects of testosterone but also other hormones like estrogens and progesterone, which may be beneficial in treating endometriosis. Relugolix has also been shown to inhibit urothelial carcinoma cells.
Propriedades químicas
Consulta técnica sobre: 3D-MEB78987 Relugolix
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
